Trials & Filings

Celgene To Present Revlimid Results at ASH

Primary endpoint met in NDMM trial

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Celgene will present data from FIRST, its Phase III study of Revlimid (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) ineligible for stem cell transplant, on Sunday, Dec. 8 during the plenary session of the American Society of Hematology annual meeting. Revlimid is not indicated for newly-diagnosed multiple myeloma in any country. A total of 1,623 patients either 65 years or older or not candidates for stem cell transplant were randomize...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters